ArticleEmerging microbes & infections2018
Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries.
Article in Emerging microbes & infections, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 3 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Extended spectrum beta-lactamase and carbapenemase-producing Acinetobacter species and Pseudomonas aeruginosa in Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2024Pooled it
- Antibiotic-resistant Acinetobacter calcoaceticus-baumannii complex in the environment: a narrative review.FEMS microbiology ecology · 2026Review
- Combined effect of eravacycline and omadacycline with other antimicrobial agents against Acinetobacter Baumannii.The Journal of antibiotics · 2026Article
- Phenotypic and Genotypic Characterization of Carbapenem-ResistantInternational journal of microbiology · 2026Article
- Review
- Harnessing the Potential of Antibacterial and Antibiofilm Phytochemicals in the Combat Against Superbugs: A One Health Perspective.Antibiotics (Basel, Switzerland) · 2025Review
- Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria.npj antimicrobials and resistance · 2025Review
- Prevalence and Antibiogram Pattern ofAntibiotics (Basel, Switzerland) · 2025Article
- Genetic profiling of multidrug-resistantMicrobiology spectrum · 2025Article
- Article
- Virulent genes related to the synthesis of community interaction factors among clinical samples of multidrug-resistant Acinetobacter baumannii in Iran.GMS hygiene and infection control · 2025Article
- Synergistic effect and mechanism of meropenem with ciprofloxacin against carbapenem-resistantFrontiers in pharmacology · 2025Article
- Article
- Epidemiology, Clinical Characteristics and Treatment Outcomes ofInfection and drug resistance · 2025Article
- Neural network-based predictions of antimicrobial resistance phenotypes in multidrug-resistantAntimicrobial agents and chemotherapy · 2024Article
- Design of multi-epitope vaccine candidate based on OmpA, CarO and ZnuD proteins against multi-drug resistantHeliyon · 2024Article
- Article
- Supercharged precision killers: Genetically engineered biomimetic drugs of screened metalloantibiotics againstScience advances · 2024Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is one of the most challenging nosocomial pathogens due to the emergence and widespread of antibiotic resistance. We aimed to provide the first analysis of global prevalence of antibiotic resistance in A. baumannii infections, by synthesizing data and knowledge through a systematic review. We searched studies reporting antibiotic resistance in A. baumannii infections using the Medline, Embase, Web of Science, and Cochrane databases from January 2000 to December 2016. Studies were eligible if they investigated and reported antibiotic resistance in A. baumannii infections with inpatients or outpatients in hospital. Our investigation showed a high prevalence of resistance to the common prescribed antibiotics in A. baumannii infections in both OECD (Organization for Economic Co-operation and Development) and non-OECD countries. Strikingly, though OECD countries have substantially lower pooled prevalence of resistance compared to non-OECD countries based on the data during 2006-2016, a further investigation in a time scale disclosed a faster increase in OECD countries during the past 11 years, and currently both of them have a comparable prevalence of resistance (2011-2016). Tigecycline and colistin are still active but their resistances are expected to become common if the preventative measures are not taken. Antibiotic resistance in A. baumannii infection developed fast and is a crisis for both OECD and non-OECD countries. A "post-antibiotic era" for A. baumannii infection is expected in the next 10-20 years without immediate actions from pharmaceutical companies and governments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.